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The severe acute res-
piratory syndrome coro-
navirus 2 (SARS-CoV-2), 
responsible for the corona-
virus disease 2019 (COV-
ID-19), is a new ribonucleic 
acid virus strain from the 
Coronaviridae family [1]. 
From December 2019 to 
June 2020, the COVID-19 
pandemic included over 7.6 
million confirmed cases in 
216 countries, and over 427,000 deaths [2]. Acute 
respiratory distress syndrome (ARDS) is one of the 
most severe complications of COVID-19 [3]. Based 
on autopsy studies, the ARDS associated with 
COVID-19 has distinct features — lung damage is 
consistent with complement-mediated microvas-
cular injury consisting of diffuse microthrombosis 
and hemorrhage, whereas the hallmarks of classic 
ARDS with alveolar damage and hyaline mem-
branes are not prominent [4]. Microvascular injury 
is typically not accompanied by gross pulmonary 
thromboembolism and parenchymal inflammation 
[5]. In addition, acro-ischemia including finger/
toe cyanosis, skin bullae and dry gangrene were 
prodromal or early symptoms of COVID-19 [6, 7], 
confirming skin damage patterns consistent with 
microvascular thrombosis. In fact, the cutaneous 
manifestations are present in up to 20% of patients 
with COVID-19 and has been classified into five 
clinical patterns, with pseudo-chilblain being the 
most, and livedo or necrosis — the least frequent 
[8]. Thus, microvascular thrombosis seems to be 
one of the main pathological findings in COVID-19 
patients [9, 10].
In addition to respiratory disease, cardio-
vascular complications are rapidly emerging as 
a key threat in COVID-19 [11]. In a recent meta-
analysis of 8 studies from China including 46,248 
infected patients, 7% of patients experienced 
myocardial injury (22% of these were critically 
ill), as evidenced by elevated cardiac troponin [12]. 
Noteworthy, patients with myocardial injury had 
higher in-hospital mortality (37.5%) than patients 
with cardiovascular disease (CVD) but without 
myocardial injury (13.3%), or patients without 
CVD (7.6%). Moreover, if myocardial injury was 
present in patients with preexisting CVD, the mor-
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myocardial injury and underlying CVD markedly 
deteriorates the prognosis in COVID-19 [14]. The 
possible mechanisms explaining this association 
include (i) cytokine storm, (ii) microangiopathy, 
(iii) viral myocarditis, (iv) stress-induced cardio-
myopathy, (iv) classic myocardial infarction due to 
infection-induced atherosclerotic plaque instability 
[15, 16]. All these mechanisms have a common 
denominator, which is endothelial injury [17, 18].
SARS-CoV-2 enters target cells through angi-
otensin-converting enzyme (ACE) two receptors, 
which are especially widely expressed on the sur-
face of lung epithelial cells and vascular endothelial 
cells in multiple organs [19, 20]. The viral infec-
tion of the endothelial cells leads to endothelial 
cell inflammation (endotheliitis). This triggers 
the immune responses responsible for a massive 
local release of pro-inflammatory cytokines and 
further aggravation of endothelial injury [21]. Since 
endothelium is indispensable for the maintenance 
of vascular homeostasis, endothelial dysfunction 
leads to vasoconstriction with subsequent organ 
ischemia and a procoagulant state. According to 
the previously mentioned meta-analysis, the most 
Figure 1. Pathophysiological mechanisms underlying the most severe complications associated with COVID-19, 
including acute respiratory distress syndrome and myocardial injury; SARS-CoV-2 — severe acute respiratory syn-
drome coronavirus 2; ACE2 — angiotensin-converting enzyme 2.
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prevalent comorbidities in the infected patients 
were those associated with preexisting endothe-
lial dysfunction, including arterial hypertension 
(17 ± 7%) and diabetes mellitus (8 ± 6%), followed 
by coronary heart disease (5 ± 4%) [12], explain-
ing why these patients have a predisposition to 
COVID-19 and worse prognosis associated with 
the infection [22].
Figure 1 summarizes the pathophysiological 
mechanisms underlying the most severe compli-
cations associated with COVID-19. Altogether, 
microvascular thrombosis and endotheliitis lead to 
impaired microcirculatory function in different vas-
cular beds, which leads to COVID-19 related com-
plications, including ARDS and myocardial injury. If 
so, therapies to improve microcirculatory function 
might prevent complications and subsequently 
improve prognosis. Established therapies to im-
prove microcirculatory function, in patients with 
microvascular angina, for example, include ACE 
inhibitors and statins [23]. However, at this time, 
nearly all major societies do not recommend add-
ing or stopping the angiotensin receptor enzyme 
inhibitors or other renin–angiotensin–aldosterone 
system antagonists in acute settings, unless done 
on clinical grounds independently of COVID-19, 
given the lack of evidence currently available on 
their potential benefit or harm [11]. Moreover, 
these therapies do not control anginal symptoms 
in up to 80% of patients with microvascular angina, 
urging the need for new treatment options [24].
The new treatment options to improve micro-
circulation function include ivabradine, nicorandil, 
ranolazine, or trimetazidine [23]. Ivabradine is 
a direct and selective inhibitor of the I(f) current in 
the sinus node, which reduces heart rate without 
affecting myocardial contractility and coronary 
vasomotor tone [25]. Nicorandil opens potassium 
channels and enhances nitric oxide production 
in vascular smooth muscle cells (VSMC), lead-
ing to vasodilation [26]. Ranolazine inhibits the 
late inward sodium channel and reduces calcium 
overload in cardiomyocytes, therefore improving 
left ventricular diastolic function and reducing 
the mechanical compression of microcirculation 
[26]. Finally, trimetazidine inhibits the reduction 
of adenosine triphosphate in cardiomyocytes, 
therefore shifting cardiac metabolism from fatty 
acid to glucose oxidation [27]. Out of the four novel 
anti-anginal agents, the combination of ranolazine 
and nicorandil seems to be especially promising 
in improving microcirculatory function due to the 
(i) complementary mechanisms of actions both 
at the cardiomyocyte and microcirculation VSMC 
level and (ii) promising preliminary results regard-
ing improvement in microcirculatory function in 
patients with microvascular angina.
Interventional treatment of impaired microcir-
culatory function could be considered as an alterna-
tive to pharmacotherapy, especially for the highest 
risk patients, with myocardial injury and with 
pre-existing endothelial dysfunction. The coronary 
sinus Reducer is a new technology designed to re-
duce disabling symptoms and improve the quality of 
life of patients with chronic refractory angina. The 
Reducer is a transcatheter, a balloon-expandable 
metal mesh, designed to create a focal narrowing 
in the lumen of the coronary sinus to generate 
a pressure gradient across it, and thus to redistrib-
ute forces of blood flow from less ischemic to more 
ischemic subendocardium of the left ventricle. The 
procedure lasts about 20–30 min, and improved 
microcirculation function is achieved within 2 
weeks following implantation, which is the time 
required for the device endothelization. In a sys-
tematic review of 6 clinical studies (n = 196), the 
Reducer device improved symptoms and objective 
indications of ischemia in 78.5% of patients [28]. 
In long-term follow-up of the first-in-man Reducer 
study (n = 14), no death or acute myocardial infarc-
tion and no device or procedure-related adverse 
events occurred up to 3 years following implanta-
tion [29]. Hence, implantation of the Reducer might 
essentially improve microcirculation function not 
only in patients with refractory angina but also in 
patients with impaired microcirculatory function 
in the course of COVID-19.
Altogether, we suggest that any strategy to 
improve microcirculatory function could prevent 
and/or attenuate the complications of COVID-19, 
especially those most severe, associated with the 
respiratory tract and cardiovascular system. Such 
strategies should be considered particularly for 
vulnerable patients with preexisting endothelial 
dysfunction, including smoking, hypertension, dia-
betes, and CVD, all of which are associated with 
adverse outcomes in COVID-19 [18, 30]. 
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